MannKind Reports FY2025 Results; United Therapeutics to Shift Tyvaso DPI Manufacturing

summarizeSummary

MannKind Corporation filed its annual 10-K report for fiscal year 2025, detailing a 22% increase in total revenues but a significant decline in net income. The report also revealed that United Therapeutics plans to shift primary manufacturing of Tyvaso DPI away from MannKind, posing a material risk to a key revenue stream.

check_boxKey Events

• Full-Year 2025 Financials

  Total revenues increased 22% to $349.0 million, driven by commercial product sales and royalties, but net income declined to $5.9 million from $27.6 million in 2024.

• Tyvaso DPI Manufacturing Shift

  United Therapeutics, a key partner, anticipates shifting primary manufacturing of Tyvaso DPI to its own facility starting in 2026, with MannKind transitioning to a secondary supplier role. This change, detailed in a January 7, 2026 amendment to the Commercial Supply Agreement, could materially impact MannKind's future revenue, as UT-related revenue accounted for 66% of total revenue in 2025.

• scPharma Acquisition & Debt

  Completed the acquisition of scPharmaceuticals Inc. in October 2025 for up to $363.5 million, adding Furoscix to its portfolio. This was partially financed by a new $325.0 million term loan from Blackstone.

• Pipeline Progress

  Anticipates PDUFA target action dates in 2026 for Afrezza pediatric indication (May 29) and Furoscix ReadyFlow Autoinjector (July 26).

auto_awesomeAnalysis

The 10-K provides a comprehensive overview of MannKind's 2025 financial performance and strategic developments. While the company achieved notable revenue growth and expanded its product portfolio through the scPharma acquisition, the most significant and concerning disclosure is United Therapeutics' plan to transition primary manufacturing of Tyvaso DPI to its own facility. Given that royalties and manufacturing revenue from United Therapeutics constituted a substantial portion (66%) of MannKind's total revenue in 2025, this shift represents a material risk to future revenue streams and profitability. Investors should closely monitor the impact of this change on MannKind's financial outlook and its ability to offset potential revenue declines through its other commercial products and pipeline advancements. The new Blackstone term loan also significantly increases the company's debt obligations.